When dosing T3, you get higher levels of Triac


Page 2

back to page 1

References

Busnardo, B., Bui, F., & Girelli, M. E. (1983). Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: Effect of an optimal saturation regimen with thyroxine or triiodothyronine. Journal of Endocrinological Investigation, 6(6), 455–461. https://doi.org/10.1007/BF03348345

Busnardo, B., Girelli, M. E., Bui, F., Zanatta, G. P., & Cimitan, M. (1980). Twenty-four hour variations of triiodothyronine (T3) levels in patients who had thyroid ablation for thyroid cancer, receiving T3 as suppressive treatment. Journal of Endocrinological Investigation, 3(4), 353–356. https://doi.org/10.1007/BF03349370

Dietrich, J. W., Landgrafe, G., & Fotiadou, E. H. (2012). TSH and Thyrotropic Agonists: Key Actors in Thyroid Homeostasis. Journal of Thyroid Research, 2012. https://doi.org/10.1155/2012/351864

Dietrich, J. W., Landgrafe-Mende, G., Wiora, E., Chatzitomaris, A., Klein, H. H., Midgley, J. E. M., & Hoermann, R. (2016). Calculated Parameters of Thyroid Homeostasis: Emerging Tools for Differential Diagnosis and Clinical Research. Frontiers in Endocrinology, 7. https://doi.org/10.3389/fendo.2016.00057

Everts, M.E.; T.J. Visser, R. Docter, M. de Jong, E.P. Krenning and G. Hennemann (1994). COMPARISON OF THE UPTAKE OF TRIIODOTHYROACETIC ACID (TRIAC) AND T3 IN CULTURED ANTERIOR PITUITARY CELLS. [Conference abstract]. American Thyroid Association. (1994). Sixty-eighth annual meeting the american thyroid association, inc. Thyroid, 4(s1), v-S-109. https://doi.org/10.1089/thy.1994.4.v

Gavin, L. A., Livermore, B. M., Cavalieri, R. R., Hammond, M. E., & Castle, J. N. (1980). Serum concentration, metabolic clearance, and production rates of 3,5,3’-triiodothyroacetic acid in normal and athyreotic man. The Journal of Clinical Endocrinology and Metabolism, 51(3), 529–534. https://doi.org/10.1210/jcem-51-3-529

Gershengorn, M. C., Geras, E., Marcus-Samuels, B. E., & Rebecchi, M. J. (1979). Receptor affinity and biological potency of thyroid hormones in thyrotropic cells. The American Journal of Physiology, 237(2), E142-146. https://doi.org/10.1152/ajpendo.1979.237.2.E142

Groeneweg, S., Peeters, R. P., Visser, T. J., & Visser, W. E. (2017). Triiodothyroacetic acid in health and disease. The Journal of Endocrinology, 234(2), R99–R121. https://doi.org/10.1530/JOE-17-0113

Ha, H. C., Jang, J. M., Zhou, D., Kim, H. G., Back, M. J., Shin, I. C., Yun, S. Y., Piao, Y., Choi, J. M., Won, J. H., & Kim, D. K. (2018). 3, 5, 3’-Triiodothyroacetic acid (TRIAC) is an anti-inflammatory drug that targets toll-like receptor 2. Archives of Pharmacal Research, 41(10), 995–1008. https://doi.org/10.1007/s12272-018-1057-8

Hoch, F. L. (1968). Biochemistry of hyperthyroidism and hypothyroidism. Postgraduate Medical Journal, 44(511), 347–362. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2466600/

Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., & Sawka, A. M. (2014). Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid, 24(12), 1670–1751. https://doi.org/10.1089/thy.2014.0028

Kawaguchi, H., Pilbeam, C. C., Woodiel, F. N., & Raisz, L. G. (1994). Comparison of the effects of 3,5,3′-triiodothyroacetic acid and triiodothyronine on bone resorption in cultured fetal rat long bones and neonatal mouse calvariae. Journal of Bone and Mineral Research, 9(2), 247–253. https://doi.org/10.1002/jbmr.5650090214

Lai, S., Zhang, S., Wang, L., Chen, Z., Fu, X., Jianhao, P., Chen, H., & Kuang, J. (2015). A Rare Mutation in Patients With Resistance to Thyroid Hormone and Review of Therapeutic Strategies. The American Journal of the Medical Sciences, 350(3), 167–174. https://doi.org/10.1097/MAJ.0000000000000538

Medina-Gomez, G., Calvo, R.-M., & Obregón, M.-J. (2004). T3 and Triac inhibit leptin secretion and expression in brown and white rat adipocytes. Biochimica Et Biophysica Acta, 1682(1–3), 38–47. https://doi.org/10.1016/j.bbalip.2004.01.007

Medina-Gomez, G., Calvo, R. M., & Obregon, M.-J. (2008). Thermogenic effect of triiodothyroacetic acid at low doses in rat adipose tissue without adverse side effects in the thyroid axis. American Journal of Physiology. Endocrinology and Metabolism, 294(4), E688-697. https://doi.org/10.1152/ajpendo.00417.2007

Mirell, C. J., Yanagisawa, M., & Hershman, J. M. (1989). Triac reduces serum TSH without decreasing alpha and beta TSH messenger RNAs. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 21(3), 123–126. https://doi.org/10.1055/s-2007-1009170

Nakamura, Y., Chopra, I. J., & Solomon, D. H. (1978). An Assessment of the Concentration of Acetic Acid and Propionic Acid Derivatives of 3,5,3’-Triiodothyronine in Human Serum. The Journal of Clinical Endocrinology & Metabolism, 46(1), 91–97. https://doi.org/10.1210/jcem-46-1-91

Piketty, M. L., d’Herbomez, M., Guillouzic, D. L., Lebtahi, R., Cosson, E., Dumont, A., Dilouya, A., & Helal, B. O. (1996). Clinical comparison of three labeled-antibody immunoassays of free triiodothyronine. Clinical Chemistry, 42(6), 933–941. http://clinchem.aaccjnls.org/content/42/6/933

Pittman, C. S., & Barker, S. B. (1959). Antithyroxine effects of some thyroxine analogues. The American Journal of Physiology, 197, 1271–1274. https://doi.org/10.1152/ajplegacy.1959.197.6.1271

Rutgers, M., Heusdens, F. A., Bonthuis, F., & Visser, T. J. (1989). Metabolism of triiodothyroacetic acid (TA3) in rat liver. II. Deiodination and conjugation of TA3 by rat hepatocytes and in rats in vivo. Endocrinology, 125(1), 433–443. https://doi.org/10.1210/endo-125-1-433

Samuels, H. H., Forman, B. M., Horowitz, Z. D., & Ye, Z. S. (1988). Regulation of gene expression by thyroid hormone. Journal of Clinical Investigation, 81(4), 957–967. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC329618/

Shinderman-Maman, E., Cohen, K., Moskovich, D., Hercbergs, A., Werner, H., Davis, P. J., Ellis, M., & Ashur-Fabian, O. (2017). Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer. Scientific Reports, 7. https://doi.org/10.1038/s41598-017-16593-x

Strømme, P., Groeneweg, S., Lima de Souza, E. C., Zevenbergen, C., Torgersbråten, A., Holmgren, A., Gurcan, E., Meima, M. E., Peeters, R. P., Visser, W. E., Høneren Johansson, L., Babovic, A., Zetterberg, H., Heuer, H., Frengen, E., Misceo, D., & Visser, T. J. (2018). Mutated Thyroid Hormone Transporter OATP1C1 Associates with Severe Brain Hypometabolism and Juvenile Neurodegeneration. Thyroid, 28(11), 1406–1415. https://doi.org/10.1089/thy.2018.0595

Visser, T. (2018, May 8). Triac: Hormone, metabolite and drug. 20th European Congress of Endocrinology. https://doi.org/10.1530/endoabs.56.S7.1

Back to article on page 1

Pages: 1 2


4 responses to “When dosing T3, you get higher levels of Triac”

  1. […] the cell nuclei receptors not only respond to T3 hormone, but also to much lower concentrations of Triac and 3’5′-T2 hormone, which are both derived from […]

  2. […] Taking “too much” at once can backfire with hypothyroid-like symptoms as too much T3 gets quickly metabolized to T2 and other derivatives like Triac. […]

  3. […] by converting a significant portion of T3 hormone to TSH-suppressive metabolites such as Triac and 3,5-T2. My experience, as well as published research and others’ clinical experience, […]

  4. […] Tiratricol, also known as ‘Triac”, has also been suggested to be the cause or a contribu… […]


Leave a public reply here, on our website.

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Discover more from Thyroid Patients Canada

Subscribe now to keep reading and get access to the full archive.

Continue reading